Milnacipran combined with pregabalin in fibromyalgia: A randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 3, 2013, Pages 113-126

  Mease, Philip J ^a   Farmer, Mildred V ^b   Palmer, Robert H ^c   Trugman, Joel M ^c   Gendreau, R Michael ^d   Wang, Yong ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Meridien Research   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Gendreau Consulting   (United States)

Author keywords

clinical trials; fibromyalgia; milnacipran; pain; pregabalin

Indexed keywords

MILNACIPRAN; PREGABALIN;

ADULT; AGED; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT GLOBAL IMPRESSION OF CHANGE SCORE; PATIENT GLOBAL IMPRESSION OF SEVERITY SCORE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; UNITED STATES; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA;

EID: 84887477142     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13483894     Document Type: Article

References (38)

1. Ablin J. Buskila D. Clauw D. (2009) Biomarkers in fibromyalgia. Curr Pain Headache Rep 13: 343–349.
2. Arnold L. (2008) Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry 69(Suppl. 2): 14–19.
3. Arnold L. (2009) Advances in the management of fibromyalgia. CNS Spectr 14: 12–16; discussion 17–18.
4. Arnold L. Clauw D. McCarberg B. (2011) Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 86: 457–464.
5. Arnold L. Gendreau R. Palmer R. Gendreau J. Wang Y. (2010 a) Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 2745–2756.
6. Arnold L. Mease P. Silverman S. (2010 b) Pregabalin: an alpha2-delta (α2-δ) ligand for the management of fibromyalgia. Am J Manag Care 16: S138–S143.
7. Arnold L. Russell I. Diri E. Duan W. Young J. Jr Sharma U. et al. (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9: 792–805.
8. Arnold L. Spera A. Baldecchi A. Wang Y. (2013) A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 26 February (Epub ahead of print).
9. Beck A. Ward C. Mendelson M. Mock J. Erbaugh J. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571.
10. Bennett R. (2009) Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am 35: 215–232.
11. Bennett R. Kamin M. Karim R. Rosenthal N. (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114: 537–545.
12. Calandre E. Morillas-Arques P. Molina-Barea R. Rodriguez-Lopez C. Rico-Villademoros F. (2011) Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord 12: 95.
13. Calandre E. Morillas-Arques P. Rodriguez-Lopez C. Rico-Villademoros F. Hidalgo J. (2007) Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry 40: 68–71.
14. Clauw D. Mease P. Palmer R. Gendreau R. (2009) The efficacy and safety of milnacipran for the treatment of fibromyalgia. Results of a randomized, double-blind, placebo-controlled trial. Clin Ther 30: 1988–2004. Erratum in Clin Ther 31: 446.
15. Crofford L. Mease P. Simpson S. Young J. Jr Martin S. Haig G. et al. (2008) Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136: 419-431.
16. Dadabhoy D. Crofford L. Spaeth M. Russell I. Clauw D. (2008) Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 10: 211.
17. Dworkin R. Turk D. Farrar J. Haythornthwaite J. Jensen M. Katz N. et al. (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113: 9–19.
18. Eli Lilly and Company (2012) Cymbalta (duloxetine), prescribing information. Available at: http://www.cymbalta.com (accessed 14 January 2013).
19. Emshoff R. Bertram S. Emshoff I. (2011) Clinically important difference thresholds of the visual analog scale: a conceptual model for identifying meaningful intraindividual changes for pain intensity. Pain 152: 2277–2282.
20. Forest Laboratories, Inc. (2012) Savella (milnacipran), prescribing information. Available at: http://www.savella.com (accessed 14 January 2013).
21. Forest Research Institute, Inc. (2007) Data on file. Milnacipran: integrated summary of safety. Jersey City, NJ: Forest Research Institute, Inc.
22. Goldenberg D. Mayskiy M. Mossey C. Ruthazer R. Schmid C. (1996) A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39: 1852–1859.
23. Kranzler J. Gendreau R. (2010) Role and rationale for the use of milnacipran in the management of fibromyalgia. Neuropsychiatr Dis Treat 6: 197–208.
24. Lachaine J. Beauchemin C. Landry P. (2010) Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 26: 284–290.
25. McCarberg B. (2012) Clinical overview of fibromyalgia. Am J Ther 19: 357–368.
26. Mease P. Arnold L. Choy E. Clauw D. Crofford L. Glass J. et al. (2009 a) Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 36: 2318-2329.
27. Mease P. Clauw D. Gendreau R. Rao S. Kranzler J. Chen W. et al. (2009 b) The efficacy and safety of milnacipran for the treatment of fibromyalgia. Results of a randomized, double-blind, placebo-controlled trial. J Rheumatol 36: 398–409. Erratum in J Rheumatol 36: 661.
28. Mease P. Russell I. Arnold L. Florian H. Young J. Jr Martin S. et al. (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35: 502–514.
29. Mease P. Seymour K. (2008) Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr Pain Headache Rep 12: 399–405.
30. Pfizer Inc. (2012) Lyrica (pregabalin), prescribing information. Available at: www.lyrica.com (accessed 14 January 2013).
31. Rivera J. Vallejo M. Esteve-Vives J. (2012) Drug prescription strategies in the treatment of patients with fibromyalgia. Rheumatol Clin 8: 184–188.
32. Seidenberg M. Haltiner A. Taylor M. Hermann B. Wyler A. (1994) Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 16: 93-104.
33. Smets E. Garssen B. Bonke B. de Haes J. (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39: 315–325.
34. Takeuchi Y. Takasu K. Ono H. Tanabe M. (2007) Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 53: 842–853.
35. Walton M. (2009) Addressing and advancing the problem of missing data. J Biopharm Stat 19: 945–956.
36. Ware J. Jr Sherbourne C. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473–483.
37. Wolfe F. Ross K. Anderson J. Russell I. Hebert L. (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38: 19–28.
38. Wolfe F. Smythe H. Yunus M. Bennett R. Bombardier C. Goldenberg D. et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160–172.